Novo Nordisk AS has released the latest data set from its ten PIONEER studies evaluating oral semaglutide, saying that the Phase IIIa PIONEER 5 trial showed its once-daily oral GLP-1 analog hit the trial goals of reducing blood sugar levels and weight in adults with type-2 diabetes.
Results of the 26-week PIONEER 5 trial, which involved 324 people with type 2 diabetes and moderate renal impairment, showed...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)